Cibenzoline: Difference between revisions
No edit summary |
Rabin Bista (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{chembox | {{chembox new | ||
| UNII_Ref = {{fdacite|correct|FDA}} | | UNII_Ref = {{fdacite|correct|FDA}} | ||
| UNII = Z7489237QT | | UNII = Z7489237QT | ||
|ImageFile= | |ImageFile=Cibenzoline Wiki Str.png | ||
|ImageSize=120px | |ImageSize=120px | ||
|IUPACName=2-(2,2-diphenylcyclopropyl)-4,5-dihydro-1''H''-imidazole | |IUPACName=2-(2,2-diphenylcyclopropyl)-4,5-dihydro-1''H''-imidazole | ||
Line 37: | Line 37: | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
Revision as of 14:22, 14 April 2015
WikiDoc Resources for Cibenzoline |
Articles |
---|
Most recent articles on Cibenzoline Most cited articles on Cibenzoline |
Media |
Powerpoint slides on Cibenzoline |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Cibenzoline at Clinical Trials.gov Clinical Trials on Cibenzoline at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Cibenzoline
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Cibenzoline Discussion groups on Cibenzoline Patient Handouts on Cibenzoline Directions to Hospitals Treating Cibenzoline Risk calculators and risk factors for Cibenzoline
|
Healthcare Provider Resources |
Causes & Risk Factors for Cibenzoline |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cibenzoline (or cifenline) is a Class Ia antiarrhythmic.